Gennev Prescription and Intake Process: How It Works, What It Costs, and Whether It's Worth It

What Gennev Actually Is

Gennev operates as a direct-to-consumer telehealth company built around menopause. It pairs patients with clinicians who have specific training in midlife hormonal changes, a niche that traditional primary care often underserves. A 2019 survey published in Menopause found that only 6.8% of OB-GYN residency programs included any formal menopause curriculum, which helps explain why platforms like Gennev have gained traction.

The company was founded in 2018 and has since expanded its clinical team, supplement line, and health coaching services. It accepts certain insurance plans and offers cash-pay options for patients without coverage or who prefer a direct relationship. Gennev is not a pharmacy. It writes prescriptions that patients fill at their own pharmacy, whether retail or mail-order.

One thing worth understanding early: Gennev also sells branded supplements and coaching packages alongside its clinical services. These revenue streams are separate from the prescription process, but the company markets them together, which can blur the line between evidence-based prescribing and wellness product sales.

How the Intake Process Works Step by Step

The Gennev intake process follows a three-phase model common to most menopause telehealth platforms. First, patients complete a structured online questionnaire covering menopause symptoms (vasomotor, genitourinary, mood, sleep), medical history, surgical history, family history of breast cancer or cardiovascular disease, and current medications.

Second, patients book a video consultation. These visits typically last 30 to 45 minutes. The clinician reviews the questionnaire responses, asks follow-up questions, and performs a risk-benefit assessment for hormone therapy based on guidelines from the North American Menopause Society (NAMS). NAMS recommends initiating hormone therapy in symptomatic women under age 60 or within 10 years of menopause onset, provided no contraindications exist [1].

Third, the clinician either writes a prescription, orders lab work, or both. Common labs include FSH, estradiol, TSH, lipid panel, and a CBC. Some patients receive prescriptions at the first visit if their symptom profile and history are straightforward. Others need labs first. This is standard practice and consistent with Endocrine Society clinical guidelines on menopausal hormone therapy [2].

The entire process from sign-up to first prescription typically takes 5 to 14 days, depending on lab turnaround and scheduling availability.

What Gennev Clinicians Can Prescribe

Gennev prescribers have access to the full formulary of FDA-approved menopausal hormone therapies. This includes systemic estradiol (oral and transdermal), micronized progesterone (Prometrium), combination estrogen-progestogen products, and low-dose vaginal estrogen formulations for genitourinary syndrome of menopause (GSM).

For patients who cannot or prefer not to use hormones, Gennev clinicians prescribe non-hormonal options. Low-dose paroxetine (Brisdelle, 7.5 mg) remains the only FDA-approved non-hormonal treatment specifically for vasomotor symptoms [3]. The newer NK3 receptor antagonist fezolinetant (Veozah, 45 mg daily) earned FDA approval in May 2023 and reduced hot flash frequency by approximately 60% at 12 weeks in the SKYLIGHT 1 trial (N=501) vs. 43% with placebo [4].

Ospemifene (Osphena) is another option Gennev providers may prescribe for dyspareunia related to vulvovaginal atrophy. The prescribing scope is limited to menopause-related conditions. Gennev clinicians do not prescribe testosterone for women (an off-label use) as a default, though some may consider it on a case-by-case basis consistent with the 2019 Global Consensus Position Statement on testosterone therapy for women [5].

Patients should ask three questions during their Gennev intake visit to ensure they receive guideline-concordant care: (1) Is my candidacy for HRT based on the NAMS timing hypothesis (under 60, within 10 years of menopause)? (2) If transdermal estradiol is not being recommended, why not, given its lower VTE risk profile? (3) What is the plan for reassessing my therapy at 3 to 5 years?

Cost Breakdown and Insurance Coverage

Gennev's pricing has shifted over time. The current model includes both insurance-billed visits and a cash-pay track. Initial consultations range from $99 to $199 for self-pay patients. Follow-up visits run approximately $75 to $149. Health coaching packages are sold separately, often bundled at $299 to $499 for multi-session plans.

For insurance patients, Gennev bills the visit as a telehealth consultation using standard CPT codes. Coverage depends entirely on the patient's plan. Out-of-pocket costs after insurance vary widely.

The medications themselves are separate from Gennev's fees. Generic oral estradiol costs roughly $10 to $30 per month at most pharmacies. Generic micronized progesterone (100 mg or 200 mg capsules) runs $15 to $40 per month. Transdermal estradiol patches (generic Climara or Vivelle-Dot equivalents) cost $30 to $80 per month without insurance. Brand-name options like Bijuva (estradiol/progesterone combination capsule) can exceed $300 per month without a manufacturer coupon. The FDA Orange Book lists all approved generic equivalents [6].

Gennev's supplement line (Vitality, Heart & Brain, Sleep) is priced at approximately $30 to $45 per bottle. These products are not FDA-regulated drugs. They do not require a prescription. The clinical evidence supporting proprietary supplement blends for menopause symptoms is weak compared to the evidence base for FDA-approved therapies. A Cochrane review of phytoestrogen supplements found no consistent benefit for hot flashes across 43 trials [7].

Is Gennev Legit? Clinical Credibility Assessment

Gennev employs board-certified clinicians. That part checks out. The question is whether specialization in menopause translates to better outcomes. There is indirect evidence that it does. A 2020 survey in the Journal of Women's Health found that clinicians with NAMS certification were significantly more likely to prescribe hormone therapy for appropriate candidates and less likely to withhold it based on outdated safety concerns from the early WHI reporting [8].

The original Women's Health Initiative trial published in 2002 found increased breast cancer risk with combined estrogen-progestin therapy (HR 1.26 to 95% CI 1.00-1.59) after a mean 5.2 years of follow-up [9]. But the WHI estrogen-only arm in hysterectomized women actually showed a non-significant reduction in breast cancer risk (HR 0.77 to 95% CI 0.59-1.01) over 6.8 years [10]. Many primary care providers still conflate these two findings, which is why menopause-specialized platforms can add real clinical value.

Gennev is not accredited by NAMS as an organization. Individual clinicians on the platform may or may not hold NCMP (NAMS Certified Menopause Practitioner) credentials. Patients should ask their assigned provider about this certification directly.

The company has not published any peer-reviewed outcome data on its patient population. No telehealth menopause platform has. This is a gap across the entire sector, not a Gennev-specific failing.

Gennev vs. Alternatives: How It Compares

Several telehealth platforms now compete in the menopause space. Midi Health, Alloy Health, and Evernow all offer similar intake-to-prescription workflows. Each has a slightly different model.

Midi Health positions itself as an insurance-first platform, accepting a broader range of plans. Alloy Health sells pre-packaged HRT products (estradiol and progesterone) direct to consumer with an integrated pharmacy, which simplifies the prescription fill process but limits formulary flexibility. Evernow uses an asynchronous intake model where patients may receive prescriptions without a live video visit, which is faster but raises questions about thoroughness of the clinical evaluation.

Gennev's differentiator is its combined model of clinical care, health coaching, and supplement sales. Whether the coaching and supplements add value depends on the individual patient. The clinical prescribing process itself is comparable to other platforms.

A key factor most patients overlook is state licensing. Telehealth menopause platforms can only prescribe in states where their clinicians hold active licenses. Gennev, Midi, Alloy, and Evernow all have coverage gaps. Patients in states with limited telehealth prescribing laws may find fewer options. The Federation of State Medical Boards (FSMB) maintains a directory of state-by-state telehealth policies [11].

For patients whose primary concern is vasomotor symptoms (hot flashes, night sweats), the choice of platform matters less than whether the prescribing clinician follows NAMS 2022 position statement recommendations. Any platform that prescribes transdermal estradiol with micronized progesterone (for patients with a uterus) is following the evidence [1].

What Happens After the Initial Visit

Post-intake, Gennev schedules follow-up visits at 4 to 12 weeks to assess treatment response. Dose adjustments are common during this period. The Endocrine Society recommends using the lowest effective dose and reassessing annually [2].

Patients starting transdermal estradiol typically begin at 0.025 mg/day or 0.0375 mg/day patches, with dose titration based on symptom response. Oral micronized progesterone is dosed at 100 mg daily (continuous) or 200 mg for 12 to 14 days per month (cyclic) in women with an intact uterus. These dosing protocols follow ACOG Practice Bulletin No. 141 on management of menopausal symptoms [12].

Lab monitoring on follow-up may include repeat estradiol levels (particularly for transdermal users where serum levels can confirm absorption), lipid panels, and liver function tests for patients on oral estrogen. Routine mammography screening continues per USPSTF guidelines (biennial for women aged 50 to 74) regardless of HRT use [13].

Prescription refills require an active patient-provider relationship. Gennev typically mandates at least one follow-up visit every 6 to 12 months to maintain prescriptions. This is standard across telehealth menopause platforms and consistent with continuity-of-care requirements in most state medical board regulations.

Red Flags to Watch For

No menopause telehealth platform should prescribe hormone therapy without screening for contraindications. Absolute contraindications to systemic estrogen include unexplained vaginal bleeding, active or history of estrogen-dependent cancers (breast, endometrial), active thromboembolic disease, active liver disease, and known clotting disorders such as Factor V Leiden or protein C/S deficiency. The American College of Obstetricians and Gynecologists lists these in its clinical guidance [12].

If a Gennev provider prescribes systemic hormone therapy without asking about personal or family history of breast cancer, VTE, stroke, or coronary heart disease, that is a quality concern. If a provider recommends Gennev-branded supplements as equivalent to or a substitute for FDA-approved HRT, that is a credibility concern.

Patients should also be cautious about compounded "bioidentical" hormone formulations. While Gennev primarily prescribes FDA-approved products, some menopause platforms and clinics promote compounded hormones as safer or more "natural." The FDA and Endocrine Society have both issued statements noting that compounded hormones lack the standardized dosing and safety monitoring of FDA-approved bioidentical products like Estrace (estradiol) and Prometrium (micronized progesterone) [6][14].

The Bottom Line on Gennev for Menopause Care

Gennev fills a real gap. Most primary care providers lack formal menopause training, and patients report an average of 4.4 years of vasomotor symptoms before receiving treatment, according to the SWAN study (N=3,302) [15]. Platforms that reduce this delay have measurable clinical value.

The prescription intake process at Gennev is straightforward and follows standard telehealth workflows. The clinical quality depends on the individual provider assigned to the patient. The supplement and coaching upsells are optional but prominently marketed, which some patients may find confusing when trying to separate medical care from wellness products.

For women experiencing moderate-to-severe vasomotor symptoms, genitourinary syndrome of menopause, or both, the most important factor is not which platform they choose. It is whether their clinician prescribes guideline-concordant therapy at an appropriate dose and monitors them with regular follow-up. The median total symptom duration across the menopausal transition is 7.4 years per SWAN data [15], meaning most patients will need a long-term treatment plan, not a one-time prescription.